Above is from LMNL presentation and is the targeted timing for Ryplazim.
Other product candidates targeted timing are for H2-2020 and H2-2021.
The Financial Position of LMNL was disclosed as follows :
As of Sept 15th, 2020 (
in Canadian $, unaudited): 
Drew down LOC $29.1M from Thomvest, 10% interest, payable quarterly, matures Apr 2024, repayable early without penalty
As of Aug 31st, 2020 (
in Canadian $, unaudited): 
Cash balance of $13.6M
$10M of long-term debt from Thomvest, 15% interest payable quarterly, matures Apr 2024, repayable early without penalty
Potential proceeds from sale of Priority Review Voucher (PRV) if Ryplazim
® is approved and PRV is granted Potential collaborations being explored for both Ryplazim
®, if approved, and fezagepras
Common shares of 23.4M with additional 2.4M options and warrants outstanding
Thomvest currently owns 71% (65.5% fully-diluted) of common shares
Above shows that LMNL is not expecting to raise any financing short term and (am assuming) will review what needs to be done after the FDA approval and review, which according to LMNL targeted timing should be Q1-2021 (or earlier).
Do what you will with the above mentioned information. GTLA
p.s Disclosure : I am still buying and averaging down. My next bids swaiting to be filled are now at USD 7.50.